AI-Developed Drugs Set for First Human Clinical Trials Soon

Key Takeaways

1. Isomorphic Labs, part of Alphabet’s DeepMind, is set to begin human clinical trials for AI-created drugs, potentially transforming drug development.
2. The technology used is based on DeepMind’s AlphaFold system, which accurately predicts protein structures and interactions, speeding up medication creation.
3. The goal is to reduce the time, cost, and risk associated with drug development, improving the success rate of early trials.
4. Founded in 2021, Isomorphic Labs has partnered with major pharmaceutical companies and secured over $600 million in funding for AI-driven drug development.
5. Their long-term vision includes creating a “cure-all” approach, allowing for the rapid design of drugs tailored to specific diseases through AI.

Isomorphic Labs, a part of Alphabet’s DeepMind, is about to make a significant move in the world of drug development. They are getting ready to kick off the first human clinical trials for drugs that have been created using artificial intelligence (AI). This could really change the game for the pharmaceutical sector.

Groundbreaking Technology

Isomorphic Labs uses advanced technology that comes from DeepMind’s renowned AlphaFold system. This system can predict protein structures accurately and can also model how they interact with other molecules. Thanks to this, new medications can be created much faster and with greater precision. Colin Murdoch, who is the President of Isomorphic Labs and also the Chief Business Officer at DeepMind, mentioned that they are “very close” to starting human trials. Right now, they are hiring more people to help with these trials.

Potential Impact on Drug Development

If things go smoothly, this could greatly change how the pharmaceutical industry works. Normally, developing drugs takes a lot of time, costs a lot of money, and is very risky, with only about a 10% success rate in early trials. Isomorphic Labs wants to use AI to make these processes much quicker, cut down on costs, and boost the chances of success. They are already working on their first internal drug candidates, particularly in oncology and immunology.

Founded in 2021, Isomorphic Labs has teamed up with big pharmaceutical companies like Eli Lilly and Novartis. In April 2025, they secured over $600 million in funding to speed up AI-driven drug development and to support the clinical trials of their active ingredients.

A Vision for the Future

The aim of Isomorphic Labs and DeepMind extends beyond just speeding up development processes. Their long-term vision is to create a “cure-all” approach using AI, which could develop suitable active ingredients based on specific clinical diagnoses. Murdoch expressed this idea clearly:

“One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease.”

If the upcoming clinical trials succeed, it could change the landscape of drug development entirely, allowing quicker access to groundbreaking therapies for various diseases. Murdoch also stated that they are working on anti-cancer drugs as well.

Source:
Link